Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2-3 mg/kg/day): 12-month prospective randomized controlled trial

Imagem de Miniatura
Arquivos
art_ZANETTI_Hydroxychloroquine_blood_levels_in_stable_lupus_nephritis_under_2021.PDF (333.46 KB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER LONDON LTD
Autores
Citação
CLINICAL RHEUMATOLOGY, v.40, n.7, p.2745-2751, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction The American Academy of Ophthalmology (2016-AAO) recommended hydroxychloroquine (HCQ) dose not to exceed 5 mg/kg/day (real body weight). Recently, it was reported that prescribed 2016-AAO dose provided adequate HCQ levels for most lupus nephritis (LN) patients, with low flare risk. However, the minimum HCQ dose required to keep adequate levels is unknown. Objectives To evaluate if a further reduction in 2016-AAO dose (2-3 mg/kg/day) would sustain 12-month HCQ levels in LN patients with stable inactive disease. Methods Seventy-three stable LN patients under prescribed full HCQ 2016-AAO dose for >= 6 months and adequate baseline HCQ levels (>= 613.5 ng/mL) were divided in two groups: reduced 2016-AAO dose (2-3 mg/kg/day), n = 32, and full 2016-AAO dose (5 mg/kg/day), n = 41. All patients were assessed at baseline, 3, 6, and 12 months. HCQ levels were measured by liquid chromatography-tandem mass spectrometry. Flare was defined as augment >= 3 in SLE Disease Activity Index-2000 and/or change in treatment. Rigorous clinical/laboratorial surveillance was performed. Results Prospective evaluation revealed for reduced 2016-AAO dose group a decrease of HCQ levels from baseline to 3 months (1,404.9 +/- 492.0 vs. 731.6 +/- 385.0 ng/mL, p < 0.01), and sustained levels at 6 months (p = 0.273) and 12 months (p = 0.091) compared to 3 months. For the full 2016-AAO dose group, a decrease occurred only from baseline to 12 months (1343.5 +/- 521.5 vs. 991.6 +/- 576.3 ng/mL, p < 0.001). Frequencies of patients with inadequate levels at 6 months was higher in reduced 2016-AAO group than full 2016-AAO dose (59% vs. 24%, p = 0.005), as well as at 12 months (66% vs. 32%, p = 0.002). Six-month and 12-month flare frequencies were comparable for both groups (p > 0.05). Conclusions Prescribed HCQ low-dose regimen (2-3 mg/kg/day) does not sustain, for most patients, 6- and 12-month adequate HCQ levels. Full 2016-AAO dose maintained HCQ levels way above this limit. Trail registration: NCT03122431, registered on April 20, 2017
Palavras-chave
Disease activity, Hydroxychloroquine, Liquid chromatography-tandem mass spectrometry, Lupus nephritis, Systemic lupus erythematosus
URI
https://observatorio.fm.usp.br/handle/OPI/41646
Referências
  1. AbuRahma AF, 2014, J AM COLL SURGEONS, V218, P797, DOI 10.1016/j.jamcollsurg.2013.12.038
  2. Browning D.J., 2014, HYDROXYCHLOROQUINE C, P35, DOI [10.1007/978-1-4939-0597-3_2, DOI 10.1007/978-1-4939-0597-3_2]
  3. Costedoat-Chalumeau N, 2006, ARTHRITIS RHEUM, V54, P3284, DOI 10.1002/art.22156
  4. Costedoat-Chalumeau N, 2019, CLIN PHARMACOL THER, V106, P374, DOI 10.1002/cpt.1194
  5. Costenbader KH, 2004, ARTHRITIS RHEUM-US, V50, P849, DOI 10.1002/art.20049
  6. Cunha C, 2018, NEPHROL DIAL TRANSPL, V33, P1604, DOI 10.1093/ndt/gfx318
  7. Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089
  8. Ghaussy NO, 2001, J RHEUMATOL, V28, P2449
  9. Gladman DD, 2002, J RHEUMATOL, V29, P288
  10. Gladman DD, 2000, J RHEUMATOL, V27, P373
  11. Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
  12. Jallouli M, 2015, ARTHRITIS RHEUMATOL, V67, P2176, DOI 10.1002/art.39194
  13. KASLOW RA, 1978, ARTHRITIS RHEUM-US, V21, P473, DOI 10.1002/art.1780210412
  14. Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
  15. MCELNAY JC, 1985, INT J PHARM, V26, P267, DOI 10.1016/0378-5173(85)90236-4
  16. Melles RB, 2014, JAMA OPHTHALMOL, V132, P1453, DOI 10.1001/jamaophthalmol.2014.3459
  17. Munster T, 2002, ARTHRITIS RHEUM-US, V46, P1460, DOI 10.1002/art.10307
  18. Pedrosa TN, 2020, LUPUS, V29, P560, DOI 10.1177/0961203320912832
  19. Petri M, 2020, ARTHRITIS RHEUMATOL, V72, P448, DOI 10.1002/art.41121
  20. Pons-Estel BA, 2018, ANN RHEUM DIS, V77, P1549, DOI 10.1136/annrheumdis-2018-213512
  21. RAGHOEBAR M, 1986, J PHARMACOL EXP THER, V238, P302
  22. Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
  23. Sumner LA, 2020, DISABIL REHABIL, V42, P1264, DOI 10.1080/09638288.2018.1522550
  24. World Health Organization, OBESITY

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/03
Carregar mais